Juvenile Arthritis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Juvenile Arthritis – Drugs In Development, 2024 report and make more profitable business decisions.
Juvenile arthritis (JA), also known as pediatric rheumatic disease, encompasses a group of inflammatory conditions affecting children and adolescents under the age of 16. This condition causes chronic joint inflammation, leading to stiffness, pain, swelling, and potential damage to joints and other tissues. Diagnosis of juvenile arthritis involves a comprehensive evaluation by a pediatric rheumatologist. It includes a physical examination, assessment of symptoms, blood tests, imaging studies (X-rays, ultrasound, MRI), and sometimes joint fluid analysis to rule out other conditions and confirm the diagnosis.
The Juvenile Arthritis drugs in development market research report provide comprehensive information on the therapeutics under development for Juvenile Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Juvenile Arthritis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Juvenile Arthritis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 43 molecules, with 40 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Juvenile Arthritis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Juvenile Arthritis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Juvenile Arthritis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncAbbVie Inc
Aprilbio Co Ltd
Bio-Thera Solutions Ltd
Bioviz Technologies Pvt Ltd
BioXpress Therapeutics SA
Changchun GeneScience Pharmaceutical Co Ltd
Delta 4 GmbH
DNX Biopharmaceuticals Inc
Eli Lilly and Co
Fresenius Kabi SwissBioSim GmbH
Galapagos NV
IcanoMAB GmbH
Immutep Ltd
IMMvention Therapeutix Inc
Intas Pharmaceuticals Ltd
Interprotein Corp
Intrinsic Medicine Inc
JSR Life Sciences LLC
Mesenbio Ltd
MetrioPharm AG
Minapharm Pharmaceuticals
Mycenax Biotech Inc
NeuClone Pty Ltd
Novartis AG
Pfizer Inc
Pharmapraxis
R-Pharm
Regeneron Pharmaceuticals Inc
Sandoz Group AG
Shilpa Biologicals Pvt Ltd
Swedish Orphan Biovitrum AB
University of California Davis School of Medicine
University of Colorado
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Juvenile Arthritis reports